| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -12,900,697 | -6,994,921 |
| Purchase of property and equipment | 567,799 | 195,343 |
| Net cash used in investing activities | -567,799 | -195,343 |
| Payments of deferred offering costs | 166,755 | - |
| Proceeds from sale of common stock, net of offering costs | 11,878,678 | 1,104,292 |
| Proceeds from exercise of stock options | 6,340 | 5,824 |
| Net cash provided by financing activities | 11,718,263 | 1,110,116 |
| Effect of foreign currency on cash | 15,587 | 36,139 |
| Net change in cash and cash equivalents | -1,734,646 | -6,044,009 |
| Cash and cash equivalents at beginning of period | 17,681,954 | - |
| Cash and cash equivalents at end of period | 15,947,308 | - |
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)